Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Cancer Vaccines01:30

Cancer Vaccines

974
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
974
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Cancer Therapies02:49

Cancer Therapies

9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neurodevelopmental regression Due to PLA2G6-associated neurodegeneration despite normal brain MRI: a case report.

Frontiers in pediatrics·2026
Same author

Metastasis in biological time.

Frontiers in cell and developmental biology·2026
Same author

Living in the dark: self-perceived health and social impacts of nationwide electricity rationing in Ecuador.

BMJ global health·2026
Same author

Authors' Reply: Methodological Concerns in AI Medical Education Frameworks.

JMIR medical education·2026
Same author

The Temporal Architecture of Human Cells: Organelle Clocks and Distributed Circadian Time.

BioEssays : news and reviews in molecular, cellular and developmental biology·2026
Same author

Programming the tumor microenvironment through microbiome-driven mechanisms.

Frontiers in cellular and infection microbiology·2026

Related Experiment Video

Updated: Jan 17, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.5K

Reprogramming cancer immunity with next-generation combination therapies.

Nikolaos C Kyriakidis1, Carolina E Echeverría2, Jhommara Bautista3,4

  • 1Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institute, Stockholm, Sweden.

Frontiers in Cell and Developmental Biology
|September 15, 2025
PubMed
Summary

Next-generation cancer immunotherapies, including checkpoint inhibitors and combination strategies, aim to overcome resistance and improve patient outcomes. Research focuses on personalized approaches, novel targets, and ensuring equitable access to advanced cancer treatments.

Keywords:
adoptive cell therapybiomarker-guided precision medicinecancer immunotherapyimmune checkpointsnext-generation therapeuticstumor microenvironment

More Related Videos

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes
10:03

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes

Published on: November 11, 2016

10.2K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.3K

Related Experiment Videos

Last Updated: Jan 17, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.5K
Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes
10:03

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes

Published on: November 11, 2016

10.2K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.3K

Area of Science:

  • Oncology
  • Immunology
  • Synthetic Biology
  • Systems Medicine

Background:

  • Cancer immunotherapy, particularly immune checkpoint inhibitors (ICIs) targeting CTLA-4 and PD-1/PD-L1, has revolutionized cancer treatment.
  • However, significant patient resistance persists due to tumor heterogeneity, metabolic reprogramming, and immunosuppressive tumor microenvironments.
  • Next-generation immunotherapies are being developed to overcome these challenges and broaden treatment applicability.

Purpose of the Study:

  • To provide a comprehensive analysis of current and emerging multimodal cancer immunotherapy strategies.
  • To explore the mechanistic basis, clinical integration, and future directions of advanced immunotherapeutic approaches.
  • To highlight the importance of biomarker-guided personalization and global equity in cancer immunotherapy.

Main Methods:

  • Review of next-generation immunotherapies including checkpoint modulators, bispecific antibodies, cell therapies, vaccines, oncolytic viruses, and cytokines.
  • Integration of nanotechnology and in vivo immune engineering for enhanced specificity and reduced toxicity.
  • Analysis of combination immunotherapy regimens, biomarker-guided strategies (e.g., tumor mutational burden, multi-omic profiling), and emerging frontiers like microbiome interventions and AI modeling.

Main Results:

  • Next-generation strategies target multiple immune regulation layers, enhancing specificity and reducing toxicity.
  • Combination immunotherapies and personalized biomarker-guided approaches are crucial for overcoming resistance.
  • Emerging frontiers like microbiome interventions and AI modeling show promise for future advancements.

Conclusions:

  • Multimodal immunotherapeutic strategies, combining diverse approaches, are essential for overcoming treatment resistance and improving durable remission rates.
  • Personalized medicine, driven by robust biomarkers and advanced modeling, will enable tailored cancer treatments.
  • Ensuring global equity in access to innovative cancer immunotherapies is critical for widespread clinical impact and achieving a curative paradigm.